Access our new interactive and instructional tool, designed to help you navigate the different treatment lines of non-driver NSCLC.

It is targeted at international (medical and radiation) oncologists and any other healthcare professionals involved in the diagnosis, treatment, and follow-up of patients with lung cancer.

Select your region:

Join Dr Mark Socinski as he guides you through this independent educational pathway for North American practice, providing expert insight and analysis to aid your own clinical decision making. The pathway tool will enable you to:
  • Utilize the latest regional recommendations and guidelines in clinical practice for first- and subsequent-line treatment of NSCLC without an actionable driver
  • Evaluate the most recent trial data on emerging treatments and combinations, and explain where and how these options may enhance the current landscape

Join Dr Enriqueta Felip (Vall d’Hebron Hospital, Barcelona, Spain) and Dr David Heigener (Helios Klinik Schleswig, Germany) as they guide you through this independent educational pathway for European practice, providing expert insight and analysis to aid your own clinical decision making. The pathway tool will enable you to:
  • Utilize the latest regional recommendations and guidelines in clinical practice for first- and subsequent-line treatment of NSCLC without an actionable driver
  • Evaluate the most recent trial data on emerging treatments and combinations, and explain where and how these options may enhance the current landscape

Join Dr Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Seoul, Korea) as she guides you through this independent educational pathway for Asian practice, providing expert insight and analysis to aid your own clinical decision making. The pathway tool will enable you to:
  • Utilize the latest regional recommendations and guidelines in clinical practice for first- and subsequent-line treatment of NSCLC without an actionable driver
  • Evaluate the most recent trial data on emerging treatments and combinations, and explain where and how these options may enhance the current landscape

  • North America
  • Europe
  • Asia
Join Dr Mark Socinski as he guides you through this independent educational pathway for North American practice, providing expert insight and analysis to aid your own clinical decision making. The pathway tool will enable you to:
  • Utilize the latest regional recommendations and guidelines in clinical practice for first- and subsequent-line treatment of NSCLC without an actionable driver
  • Evaluate the most recent trial data on emerging treatments and combinations, and explain where and how these options may enhance the current landscape
Join Dr Enriqueta Felip (Vall d’Hebron Hospital, Barcelona, Spain) and Dr David Heigener (Helios Klinik Schleswig, Germany) as they guide you through this independent educational pathway for European practice, providing expert insight and analysis to aid your own clinical decision making. The pathway tool will enable you to:
  • Utilize the latest regional recommendations and guidelines in clinical practice for first- and subsequent-line treatment of NSCLC without an actionable driver
  • Evaluate the most recent trial data on emerging treatments and combinations, and explain where and how these options may enhance the current landscape
Join Dr Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Seoul, Korea) as she guides you through this independent educational pathway for Asian practice, providing expert insight and analysis to aid your own clinical decision making. The pathway tool will enable you to:
  • Utilize the latest regional recommendations and guidelines in clinical practice for first- and subsequent-line treatment of NSCLC without an actionable driver
  • Evaluate the most recent trial data on emerging treatments and combinations, and explain where and how these options may enhance the current landscape

Background

In a time of rapid advances and ever expanding treatment options, it is becoming increasingly difficult to keep up to date with all the evidence-based recommendations, trial data, and emerging therapies.

This tool has been designed to help navigate the different treatment lines of non-driver NSCLC, enhanced by leading expert opinion, learning resources, and relevant data summaries.

Educational grant

This activity is supported by an education grant from Eli Lilly and Company.

Further resources

Expert videos and a scientific summary titled: Simplifying the sequencing of treatment in NSCLC patients with no actionable mutations are also available here.

Dr Myung-Ju Ahn

Myung-Ju Ahn is Professor of Hemato-Oncology in the Department of Medicine at Sungkyunkwan University School of Medicine in Seoul, Korea. She is a member of numerous associations and societies dedicated to cancer research, such as the International Society of Lung Cancer Association, the American Association of Cancer Research, the American Society of Clinical Oncology, the Korean Society of Medical Oncology and the Korean Cancer Study Group, where she is also Chief of the executive committee and chairperson of Lung Cancer Disease Committee. She was a president of the Korean Society of Medical Oncology (2018-2019) and she was a president of the Multidisciplinary Immuno-oncology Study Group (2017-2018). She serves as a board member for the Korean Association of Cancer and the Korean Society of Medical Oncology, Korean Association for Lung Cancer, and Korean Association for Cancer, and also serves on the Editorial board of Journal of Thoracic Oncology.

Professor Ahn received her education from Hanyang University College of Medicine in Seoul, where she earned her medical degree, as well as her doctorate. She completed her residency training in internal medicine at Hanyang University Hospital, and held numerous fellowships, including a postdoctoral research fellowship at the Memorial Sloan-Kettering Cancer Center in New York, USA.

Professor Ahn has authored or co-authored over 250 publications. Her research interests include the development of predictive and prognostic marker in lung cancer in terms of personalized therapy, and her recent research focuses on the early clinical trial for the development of drug discovery and reposition of targeted drugs, as well as the development of NSCLC genome atlas. In recognition of her dedication to cancer research, she has been awarded multiple honours, including the 2003 Best Researcher Award from the Korean Medical Women’s Association, the 2015 Best Researcher Award from the Korean Association of Clinical Oncology, and the 2018 Boryoung Scientific Award from the Korean Cancer Research Foundation.

Disclosures

Dr Ahn discloses she has received grant and/or research support from AstraZeneca, Lilly, Merck, Takeda, BMS, Pfizer. She has also been in receipt of honoraria or consultation fees from AstraZeneca, Lilly, Merck, Takeda, BMS, Pfizer, Alpha pharmaceuticals.

Dr David Heigener

David F. Heigener is head of the department of pulmonology at the Helios Klinik Schleswig, Germany. His main interest is medical treatment of lung cancer. He participated in numerous trials in this field with approximately 100 publications and book contributions. He is also a member of the palliative care task force in the German Respiratory Society (Deutsche Gesellschaft für Pneumologie).

Professor Heigener is Member of IASLC, ESMO, German Respiratory Society (DGP), German Cancer Society (DKG) and the German Society for Palliative Medicine (DGP). He is on the Editorial Board of Atemwegs- und Lungenkrankheiten and Reviewer for The Lancet, The Lancet Oncology, Lung Cancer, Respiratory Medicine, Annals of Oncology, British Medical Journal, Journal of Clinical Oncology and Journal of Thoracic Oncology.

Disclosures

David Heigener has no conflicts of interests to disclose.

Dr Enriqueta Felip

Enriqueta Felip is the Head of the Thoracic Cancer Unit within the Oncology Department of Vall d’Hebron Hospital, Barcelona, Spain. Professor Felip is in charge of thoracic malignancy management, and is responsible for thoracic cancer trials undertaken by the Oncology Department. She is also Associate Professor at the Autonomous University of Barcelona (UAB). Dr Felip received her medical degree from the UAB, where she also completed her PhD studies in medical oncology. She is involved in the training of medical students, residents and particularly in mentoring fellows.

Dr Felip is currently a member of the Spanish Lung Cancer Group (SLCG), the Spanish Society of Medical Oncology (SEOM), the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the International Association for the Study of Lung Cancer (IASLC). Dr Felip has been involved in several initiatives with scientific organizations, among them, as Subject Editor of Guidelines Working group ESMO Minimum Clinical Recommendations in lung cancer and Coordinator of the 1st ESMO Consensus Conference in lung cancer. Dr Felip is at present a member of the scientific committee of the SLCG and coordinator of the European School of Oncology (ESO) lung cancer program. Dr Felip is also author of many peer-reviewed articles and book chapters relating to the field of thoracic malignancies.

Disclosures

Enriqueta Felip has the following disclosures: Receipt of grants/research supports: Fundaci6n Merck Salud, Grant for Oncology Innovation EMD Serano. Consulting, advisory role or speaker’s bureau: AbbVie, AstraZeneca, BerGenBio, Blueprint medicines, Boehringer lngelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Guardant Health, Janssen, Medscape, Merck KGaA, Merck Sharp & Dahme, Novartis, Pfizer, Roche, Samsung, Takeda, Touchtime.

Dr Mark Socinski

Mark A. Socinski is the Executive Medical Director of the Advent Health Cancer Institute in Orlando, FL. He received his medical degree from the University of Vermont, College of Medicine, and he completed his postdoctoral training including an internship and residency in internal medicine at the Beth Israel Hospital, and medical oncology fellowship at the Dana-Farber Cancer Institute, both at Harvard Medical School.

Dr Socinski has held posts as Director of the Lung Cancer Section at the University of Pittsburgh Medical Center, Clinical Associate Director of the University of Pittsburgh Lung Cancer Specialized Program of Research Excellence (SPORE), Co-Director of UPMC Lung Cancer Center of Excellence, and Co-Leader of the Lung Cancer Program at the University of Pittsburgh Cancer Institute. He is a member of numerous professional societies, such as the American College of Physicians (ACP), American Society of Clinical Oncology (ASCO), Cancer and Leukemia Group B (Alliance), International Association for the Study of Lung Cancer (IASLC), and American College of Chest Physicians.

Dr Socinski is also co-Chair Emeritus of the Thoracic Malignancies Steering Committee for the National Cancer Institute. Dr Socinski is well-published in peer-reviewed literature, including the New England Journal of Medicine, Journal of Clinical Oncology, Journal of Thoracic Oncology, Cancer, and The Lancet Oncology. His primary research interests cover all aspects of clinical trials related to the thoracic oncology population. He also has been instrumental in the development of many cooperative group and investigator-initiated clinical trials.

Disclosures

Mark Socinski discloses that he has received grant support, honoraria and/or served on a speakers’ bureau for Genentech, Novartis, AstraZeneca, Spectrum, Guardant Health, and Bayer.